CStone Pharmaceuticals-B plans to repurchase up to 136 million shares. The latest clinical data for CS2009 will be disclosed at the ASCO Annual Meeting.

CStone Pharmaceutical-B (02616) is up more than 4%; as of press time, it's up 2.54% at HK$8.07, with a turnover of HK$21.84 million.

Zhitong FinanceMay 14 09:43

CStone Pharmaceuticals-B (02616) plans to repurchase up to 136 million shares on the open market.

CStone Pharmaceuticals-B (02616) announced that, pursuant to the general mandate approved by the company's shareholders at the annual general meeting held on June 25, 2025, and (if applicable) any general mandate for share repurchases approved by future shareholders at subsequent general meetings from time to time (the Repurchase Mandate), it intends to repurchase up to a maximum of 136 million shares on the open market from time to time.

Zhitong FinanceMay 13 17:58

H-share announcements | Dama Entertainment issues profit alert, expecting annual net profit attributable to shareholders to be no less than 700 million yuan

Guofu Quantum and Yitusheng Technology have entered into a strategic cooperation memorandum of understanding, planning to jointly establish a quantum computing center in Hong Kong; Dama Entertainment announced a profit alert, expecting its annual net profit attributable to shareholders to be no less than 700 million yuan.

Zhitong FinanceMay 11 09:00

CStone Pharmaceuticals-B (02616.HK): Initiated nationwide commercial shipment of Pralsetinib capsules for real estate integration.

Gelonghui, May 11th丨CStone Pharmaceuticals-B (02616.HK) announced that the first batch of locally produced products of its highly selective RET inhibitor, pralsetinib capsules (100mg), has completed production and release, and nationwide commercial shipments have officially commenced. This marks a critical step towards the domestic supply chain independence for this innovative drug. Pralsetinib capsules were included for the first time in the 'National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogue' ('National Medical Insurance Catalogue') at the end of 2025 and will take effect from January 1, 2026. Benefiting from the significant improvement in patient accessibility due to inclusion in the National Medical Insurance Catalogue,

Gelonghui FinanceMay 11 08:04

As the ASCO annual meeting approaches, the number of LBA for domestically innovative drugs has reached a new high, with three key investment themes worth noting.

A total of 63 studies were selected as Late-Breaking Abstracts (LBA) at this year's ASCO, including 13 studies from 12 companies based in China; notable domestically developed innovative drugs selected for LBA include AK112 from Akeso Biopharma and sintilimab plus chemotherapy from Innovent Bio; Huatai Securities stated that China's innovative drug sector is rapidly emerging as a defining force in global oncology treatment paradigms, with first-line lung cancer being one of the key focuses at this year’s ASCO.

cls.cnMay 4 14:15

Orient Securities: As the ASCO event approaches, China's innovative drug sector is making a strong breakthrough.

Recently, the official theme of the 2026 ASCO conference was announced, which is expected to significantly enhance the academic value, clinical value, and global competitiveness of domestically innovative drugs.

Zhitong FinanceApr 29 11:10